1144080-27-2

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate is used as a synthetic intermediate for the creation of various organic compounds due to its unique structure and potential reactivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate is used as a precursor in the development of pharmaceuticals, leveraging its specific molecular features to contribute to the design of new drugs.
Used in Pharmaceutical Development:
Tert-butyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)hydrazinecarboxylate is used as a building block in the synthesis of complex molecules and pharmaceuticals, potentially leading to the discovery of novel therapeutic agents.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 870-46-2 t-butoxycarbonylhydrazine 

Downstream Products

• 1144080-29-4 1,4-dioxaspiro[4.5]decan-8-ylhydrazine 

Relevant academic research and scientific papers

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent

A series of pyrazolopyrimidine mammalian Target Of Rapamycin (mTOR) inhibitors with various substituents at the 1-position have been prepared, resulting in compounds with excellent potency, selectivity and microsomal stability. Combination of a 1-cyclohexyl ketal group with a 2,6-ethylene bridged morpholine in the 4-position and a ureidophenyl group in the 6-positon resulted in compound 8a, that selectively suppressed key mTOR biomarkers in vivo for at least 8 h following iv administration and showed excellent oral activity in a xenograft tumor model.